BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 24146170)

  • 1. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation.
    Bakker SF; Dik VK; Witte BI; Lips P; Roos JC; Van Bodegraven AA
    J Crohns Colitis; 2013 Jun; 7(5):377-84. PubMed ID: 22749232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the role for bisphosphonates in IBD?
    Bernstein CN; Targownik LE; Leslie WD
    Gut; 2014 Sep; 63(9):1369-70. PubMed ID: 24221457
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
    Siffledeen JS; Fedorak RN; Siminoski K; Jen H; Vaudan E; Abraham N; Steinhart H; Greenberg G
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):122-32. PubMed ID: 15704046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
    Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
    J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of risedronate in osteopenia in Crohn's disease.
    Buchan A; Manuel A
    Gut; 2015 Jan; 64(1):185. PubMed ID: 24304669
    [No Abstract]   [Full Text] [Related]  

  • 9. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
    Henderson S; Hoffman N; Prince R
    Am J Gastroenterol; 2006 Jan; 101(1):119-23. PubMed ID: 16405543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Authors' response: The role of risedronate in osteopenia in Crohn's disease.
    van Bodegraven AA; Witte BI; Lips P;
    Gut; 2015 Jan; 64(1):185-6. PubMed ID: 24569060
    [No Abstract]   [Full Text] [Related]  

  • 11. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
    Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD; Faber H; Farahmand P; Dorst A
    Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
    Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
    Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
    Sato Y; Iwamoto J; Honda Y
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1390-3. PubMed ID: 21825080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.